The first, recently published, phase I clinical trial (AUGMENT-101 (NCT04065399)) on revumenib (previously known as SNDX-5613), a selective oral inhibitor of the menin–KMT2A interaction, investigated the effect of this drug in R/R AML. The gene discussed is KMT2A; the disease is acute myeloid leukemia.